LGM
RLMD icon

Logos Global Management’s Relmada Therapeutics RLMD Stock Holding History

Logos Global Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-400,000
Closed -$9.01M – 61
2021
Q4 		$9.01M Buy
+400,000
New +$8.89M 0.93% 28

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Logos Global Management's RLMD Position: Q1 2022 in Review

Logos Global Management sold out of Relmada Therapeutics (RLMD) in Q1 2022, closing a stake of 400,000 shares — an estimated $9.01M sold.

Logos Global Management first reported a position in RLMD in Q4 2021 and held it in 1 quarter. The position peaked at $9.01M in Q4 2021. 113 funds tracked by Wall St. Rank hold RLMD as of Q1 2022.

  • Logos Global Management reported no remaining Relmada Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Logos Global Management sold 400,000 Relmada Therapeutics shares in Q1 2022, an estimated $9.01M.
  • Logos Global Management first reported a position in Relmada Therapeutics in Q4 2021 and held it in 1 quarter.
  • Logos Global Management's Relmada Therapeutics position peaked at $9.01M in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2022.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.